
July 10 (Reuters) - Pfizer Inc PFE.N:
XTANDI® PLUS LEUPROLIDE SIGNIFICANTLY IMPROVES SURVIVAL OUTCOMES IN MEN WITH NON-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH HIGH-RISK BIOCHEMICAL RECURRENCE
PFIZER: EMBARK MET KEY SECONDARY ENDPOINT
PFIZER INC - XTANDI PLUS LEUPROLIDE IMPROVES OVERALL SURVIVAL
PFIZER: NO NEW SAFETY SIGNALS WERE OBSERVED IN ANALYSIS, AND SAFETY RESULTS WERE CONSISTENT WITH DEMONSTRATED SAFETY PROFILE OF XTANDI